Cargando…

Design issues in crossover trials involving patients with Parkinson’s disease

BACKGROUND AND OBJECTIVES: Crossover designs are frequently used to assess treatments for patients with Parkinson’s disease. Typically, two-period two-treatment trials include a washout period between the 2 periods and assume that the washout period is sufficiently long to eliminate carryover effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Sparrow, David, DeMolles, Deborah, Dubaz, Ornella, Durso, Raymon, Rosner, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476358/
https://www.ncbi.nlm.nih.gov/pubmed/37670777
http://dx.doi.org/10.3389/fneur.2023.1197281
_version_ 1785100912558080000
author Sparrow, David
DeMolles, Deborah
Dubaz, Ornella
Durso, Raymon
Rosner, Bernard
author_facet Sparrow, David
DeMolles, Deborah
Dubaz, Ornella
Durso, Raymon
Rosner, Bernard
author_sort Sparrow, David
collection PubMed
description BACKGROUND AND OBJECTIVES: Crossover designs are frequently used to assess treatments for patients with Parkinson’s disease. Typically, two-period two-treatment trials include a washout period between the 2 periods and assume that the washout period is sufficiently long to eliminate carryover effects. A complementary strategy might be to jointly model carryover and treatment effects, though this has rarely been done in Parkinson’s disease crossover studies. The primary objective of this research is to demonstrate a modeling approach that assesses treatment and carryover effects in one unified mixed model analysis and to examine how it performs in a simulation study and a real data analysis example, as compared to other data analytic approaches used in Parkinson’s disease crossover studies. METHODS: We examined how three different methods of analysis (standard crossover t-test, mixed model with a carryover term included in model statement, and mixed model with no carryover term) performed in a simulation study and illustrated the methods in a real data example in Parkinson’s disease. RESULTS: The simulation study based on the presence of a carryover effect indicated that mixed models with a carryover term and an unstructured correlation matrix provided unbiased estimates of treatment effect and appropriate type I error. The methods are illustrated in a real data example involving Parkinson’s disease. Our literature review revealed that a majority of crossover studies included a washout period but did not assess whether the washout was sufficiently long to eliminate the possibility of carryover. DISCUSSION: We recommend using a mixed model with a carryover term and an unstructured correlation matrix to obtain unbiased estimates of treatment effect.
format Online
Article
Text
id pubmed-10476358
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104763582023-09-05 Design issues in crossover trials involving patients with Parkinson’s disease Sparrow, David DeMolles, Deborah Dubaz, Ornella Durso, Raymon Rosner, Bernard Front Neurol Neurology BACKGROUND AND OBJECTIVES: Crossover designs are frequently used to assess treatments for patients with Parkinson’s disease. Typically, two-period two-treatment trials include a washout period between the 2 periods and assume that the washout period is sufficiently long to eliminate carryover effects. A complementary strategy might be to jointly model carryover and treatment effects, though this has rarely been done in Parkinson’s disease crossover studies. The primary objective of this research is to demonstrate a modeling approach that assesses treatment and carryover effects in one unified mixed model analysis and to examine how it performs in a simulation study and a real data analysis example, as compared to other data analytic approaches used in Parkinson’s disease crossover studies. METHODS: We examined how three different methods of analysis (standard crossover t-test, mixed model with a carryover term included in model statement, and mixed model with no carryover term) performed in a simulation study and illustrated the methods in a real data example in Parkinson’s disease. RESULTS: The simulation study based on the presence of a carryover effect indicated that mixed models with a carryover term and an unstructured correlation matrix provided unbiased estimates of treatment effect and appropriate type I error. The methods are illustrated in a real data example involving Parkinson’s disease. Our literature review revealed that a majority of crossover studies included a washout period but did not assess whether the washout was sufficiently long to eliminate the possibility of carryover. DISCUSSION: We recommend using a mixed model with a carryover term and an unstructured correlation matrix to obtain unbiased estimates of treatment effect. Frontiers Media S.A. 2023-08-21 /pmc/articles/PMC10476358/ /pubmed/37670777 http://dx.doi.org/10.3389/fneur.2023.1197281 Text en Copyright © 2023 Sparrow, DeMolles, Dubaz, Durso and Rosner. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Sparrow, David
DeMolles, Deborah
Dubaz, Ornella
Durso, Raymon
Rosner, Bernard
Design issues in crossover trials involving patients with Parkinson’s disease
title Design issues in crossover trials involving patients with Parkinson’s disease
title_full Design issues in crossover trials involving patients with Parkinson’s disease
title_fullStr Design issues in crossover trials involving patients with Parkinson’s disease
title_full_unstemmed Design issues in crossover trials involving patients with Parkinson’s disease
title_short Design issues in crossover trials involving patients with Parkinson’s disease
title_sort design issues in crossover trials involving patients with parkinson’s disease
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476358/
https://www.ncbi.nlm.nih.gov/pubmed/37670777
http://dx.doi.org/10.3389/fneur.2023.1197281
work_keys_str_mv AT sparrowdavid designissuesincrossovertrialsinvolvingpatientswithparkinsonsdisease
AT demollesdeborah designissuesincrossovertrialsinvolvingpatientswithparkinsonsdisease
AT dubazornella designissuesincrossovertrialsinvolvingpatientswithparkinsonsdisease
AT dursoraymon designissuesincrossovertrialsinvolvingpatientswithparkinsonsdisease
AT rosnerbernard designissuesincrossovertrialsinvolvingpatientswithparkinsonsdisease